As per NPPA Order S.O. 5690(E) dated 17 October 2026, the trade margin on 137 non-scheduled anti-cancer medicines is capped at 30%. Hetero’s revised MRPs take effect on 9 November 2026.
Patients and partners with questions about the revised prices are welcome to speak to their doctor, pharmacist or hospital.
Source: NPPA Order S.O. 5690(E), The Gazette of India, 17 October 2026.
The DIASPA Division of Hetero Healthcare is focused on providing comprehensive therapeutic solutions for diabetes and associated metabolic health conditions. With diabetes requiring continuous and individualised management, the division aims to support healthcare professionals with therapeutic options that help address glycaemic management and the broader healthcare needs of people living with diabetes.
Its portfolio encompasses oral antidiabetic therapies and combination approaches that support blood glucose management through different mechanisms of action. The division’s therapeutic focus extends to the management of type 2 diabetes and related metabolic concerns, supporting a more comprehensive approach to long-term diabetes care.
Backed by Hetero Healthcare’s commitment to quality, accessibility, innovation, and patient-centric care, DIASPA strives to provide dependable therapeutic options that support effective diabetes management. Through its focused portfolio, the division continues to address evolving clinical needs and contribute towards better long-term metabolic health and patient outcomes.
View by-
